Core Viewpoint - The stock of Bolekang Vision Cloud-B (02592) has experienced significant volatility, with a nearly 15% drop and a more than 40% decline since December 5, following a rapid price increase that saw the stock double in value over just 10 trading days from November 21 to December 4 [1] Company Developments - Bolekang Vision announced that its wholly-owned subsidiary, ADS Therapeutics LLC, submitted a new drug clinical trial application for CBT-199, a potential best-in-class ophthalmic candidate, to the U.S. Food and Drug Administration on December 15 [1] - CBT-199 has been undergoing safety and tolerability assessments in preclinical animal studies since June 2023, with expectations that these studies will support future clinical trials [1] - On January 3, two cornerstone investors of Bolekang Vision will face a lock-up expiration for their shares [1]
港股异动 | 拨康视云-B(02592)一度跌近15% CBT-199眼科候选药物在美递交新药临床试验申请